The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 study
Aurélien Voissière, Carlos Gomez-Roca, View ORCID ProfileSylvie Chabaud, View ORCID ProfileCéline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, View ORCID ProfileIsabelle Treilleux, View ORCID ProfileLauriane Eberst, View ORCID ProfileCatherine Terret, View ORCID ProfileIphigénie Korakis, Gwenaelle Garin, David Pérol, View ORCID ProfileJean-Pierre Delord, View ORCID ProfileChristophe Caux, View ORCID ProfileBertrand Dubois, View ORCID ProfileChristine Ménétrier-Caux, View ORCID ProfileNathalie Bendriss-Vermare, View ORCID ProfilePhilippe A. Cassier
doi: https://doi.org/10.1101/2023.02.15.23285939
Aurélien Voissière
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France
Carlos Gomez-Roca
2Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Sylvie Chabaud
3Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France
Céline Rodriguez
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France
4Laboratory of Cancer Immunotherapy of Lyon (LICL), Centre Léon Bérard, 69008 Lyon, France
Axelle Nkodia
4Laboratory of Cancer Immunotherapy of Lyon (LICL), Centre Léon Bérard, 69008 Lyon, France
Justine Berthet
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France
4Laboratory of Cancer Immunotherapy of Lyon (LICL), Centre Léon Bérard, 69008 Lyon, France
Laure Montane
3Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France
Anne-Sophie Bidaux
3Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France
Isabelle Treilleux
5Biopathology Department, Centre Léon Bérard, Lyon, France
Lauriane Eberst
6Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec 69008 Lyon, France
Catherine Terret
6Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec 69008 Lyon, France
Iphigénie Korakis
2Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Gwenaelle Garin
3Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France
David Pérol
3Clinical Research Platform (DRCI), Centre Léon Bérard, Lyon, France
Jean-Pierre Delord
2Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Christophe Caux
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France
4Laboratory of Cancer Immunotherapy of Lyon (LICL), Centre Léon Bérard, 69008 Lyon, France
Bertrand Dubois
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France
4Laboratory of Cancer Immunotherapy of Lyon (LICL), Centre Léon Bérard, 69008 Lyon, France
Christine Ménétrier-Caux
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France
4Laboratory of Cancer Immunotherapy of Lyon (LICL), Centre Léon Bérard, 69008 Lyon, France
Nathalie Bendriss-Vermare
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Cancer Research Center of Lyon, Lyon, France
4Laboratory of Cancer Immunotherapy of Lyon (LICL), Centre Léon Bérard, 69008 Lyon, France
Philippe A. Cassier
6Department of Medical Oncology, Centre Léon Bérard, 28 rue Laennec 69008 Lyon, France
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
- supplemental material[supplements/285939_file02.pdf]
Posted February 23, 2023.
The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 study
Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, Catherine Terret, Iphigénie Korakis, Gwenaelle Garin, David Pérol, Jean-Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare, Philippe A. Cassier
medRxiv 2023.02.15.23285939; doi: https://doi.org/10.1101/2023.02.15.23285939
The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 study
Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, Céline Rodriguez, Axelle Nkodia, Justine Berthet, Laure Montane, Anne-Sophie Bidaux, Isabelle Treilleux, Lauriane Eberst, Catherine Terret, Iphigénie Korakis, Gwenaelle Garin, David Pérol, Jean-Pierre Delord, Christophe Caux, Bertrand Dubois, Christine Ménétrier-Caux, Nathalie Bendriss-Vermare, Philippe A. Cassier
medRxiv 2023.02.15.23285939; doi: https://doi.org/10.1101/2023.02.15.23285939
Subject Area
Subject Areas
- Addiction Medicine (326)
- Allergy and Immunology (642)
- Anesthesia (170)
- Cardiovascular Medicine (2452)
- Dermatology (208)
- Emergency Medicine (384)
- Epidemiology (11896)
- Forensic Medicine (10)
- Gastroenterology (707)
- Genetic and Genomic Medicine (3828)
- Geriatric Medicine (356)
- Health Economics (646)
- Health Informatics (2470)
- Health Policy (954)
- Hematology (348)
- HIV/AIDS (806)
- Medical Education (379)
- Medical Ethics (105)
- Nephrology (409)
- Neurology (3595)
- Nursing (202)
- Nutrition (536)
- Oncology (1865)
- Ophthalmology (544)
- Orthopedics (228)
- Otolaryngology (293)
- Pain Medicine (235)
- Palliative Medicine (68)
- Pathology (457)
- Pediatrics (1057)
- Primary Care Research (432)
- Public and Global Health (6259)
- Radiology and Imaging (1317)
- Respiratory Medicine (842)
- Rheumatology (387)
- Sports Medicine (332)
- Surgery (418)
- Toxicology (51)
- Transplantation (177)
- Urology (149)